Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | -1.32% | -7.41% | -44.44% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 86.72 | 121.3 | 114.6 | 72.5 | 50.22 | 28.22 | - |
Enterprise Value (EV) 1 | 86.72 | 121.3 | 114.6 | 72.5 | 50.22 | 28.22 | 28.22 |
P/E ratio | - | - | -7.72 x | -2.33 x | -1.73 x | -1.74 x | -2.73 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,334 | 14,393 | 18,331 | 18,412 | 18,599 | 18,812 | - |
Reference price 2 | 8.391 | 8.430 | 6.250 | 3.938 | 2.700 | 1.500 | 1.500 |
Announcement Date | 30/04/20 | 30/04/21 | 29/04/22 | 31/03/23 | 29/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -8.619 | -9.785 | -19.29 | -25.8 | -29.4 | -16.3 | -12 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | -14.47 | -31.06 | -29.07 | -16.3 | -12 |
Net income 1 | - | - | -14.47 | -31.06 | -29.07 | -16.3 | -12 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | - | - | -0.8100 | -1.690 | -1.560 | -0.8600 | -0.5500 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 30/04/20 | 30/04/21 | 29/04/22 | 31/03/23 | 29/03/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.864 | -7.814 | -6.404 | -5.871 | -5.677 | -7.845 | -6.783 | -6.649 | -5.628 | -10.34 | -4.6 | -4.4 | -3.8 | -3.5 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -4.736 | -8.225 | -9.913 | -5.733 | -7.189 | -7.218 | -6.792 | -5.963 | -9.095 | -4.6 | -4.4 | -3.8 | -3.5 | - |
Net income 1 | - | -4.736 | -8.225 | -9.913 | -5.733 | -7.189 | -7.218 | -6.792 | -5.963 | -9.095 | -4.6 | -4.4 | -3.8 | -3.5 | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | - | -0.2600 | -0.4500 | -0.5400 | -0.3100 | -0.3900 | -0.3900 | -0.3700 | -0.3200 | -0.4800 | -0.2500 | -0.2400 | -0.2000 | -0.1700 | -0.1400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 19/11/21 | 29/04/22 | 27/05/22 | 22/08/22 | 02/12/22 | 31/03/23 | 16/06/23 | 01/09/23 | 09/11/23 | 29/03/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.19 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 30/04/20 | 30/04/21 | 29/04/22 | 31/03/23 | 29/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.44% | 28.22M | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.44% | 22.25B | |
-13.14% | 22.09B | |
-7.91% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ENLV Stock
- Financials Enlivex Therapeutics Ltd.